Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial

NACompletedINTERVENTIONAL
Enrollment

32,771

Participants

Timeline

Start Date

November 20, 2020

Primary Completion Date

July 29, 2022

Study Completion Date

July 29, 2023

Conditions
Uterine Cervical NeoplasmUterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine Cervical DiseasesUterine DiseasesCervical CancerCervical DysplasiaHuman Papilloma VirusHPV-Related Cervical CarcinomaHPV InfectionHPV-Related Malignancy
Interventions
OTHER

Usual Care

Subjects will receive Kaiser Permanente Washington standard of care.

BEHAVIORAL

Education

Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening.

BEHAVIORAL

Direct Mail

Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will also receive an insert describing the home-based cervical cancer screening option and that a kit will be sent within 1 week. An HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.

BEHAVIORAL

Opt-in

Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will receive an Opt-in Insert describing the home-based cervical cancer screening option and how to request a kit. Individuals can request a kit by phone or through a webpage. Individuals who request a kit will receive the HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.

Trial Locations (1)

98101

Kaiser Permanente Washington Health Research Institute, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

University of Washington

OTHER

collaborator

University of Texas Southwestern Medical Center

OTHER

lead

Kaiser Permanente

OTHER

NCT04679675 - Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial | Biotech Hunter | Biotech Hunter